Onxeo SA - ESG Rating & Company Profile powered by AI
This analysis of Onxeo SA was prepared by All Street Sevva using advanced machine learning. This Sustainability score for Onxeo SA indicates its reporting of the United Nations SDGs. If you are employed by Onxeo SA and you would like to licence your ESG rating, please contact us.
Onxeo SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.6; made up of an environmental score of 2.7, social score of 3.2 and governance score of 2.0.
2.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1437 | Valenta Farmatsevtika AO | 2.7 | Medium |
| 1437 | Wockhardt Bio AG | 2.7 | Medium |
| 1481 | Onxeo SA | 2.6 | Medium |
| 1481 | CTI Biopharma Corp | 2.6 | Medium |
| 1481 | Cannara Biotech Inc | 2.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Onxeo SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Onxeo SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Onxeo SA report the average age of the workforce?
Sign up for free to unlockDoes Onxeo SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Onxeo SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Onxeo SA disclose cybersecurity risks?
Sign up for free to unlockDoes Onxeo SA offer flexible work?
Sign up for free to unlockDoes Onxeo SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Onxeo SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Onxeo SA conduct supply chain audits?
Sign up for free to unlockDoes Onxeo SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Onxeo SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Onxeo SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Onxeo SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Onxeo SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Onxeo SA disclose water use targets?
Sign up for free to unlockDoes Onxeo SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Onxeo SA have a product recall in the last two years?
Sign up for free to unlockDoes Onxeo SA disclose incidents of discrimination?
Sign up for free to unlockDoes Onxeo SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Onxeo SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Onxeo SA disclose parental leave metrics?
Sign up for free to unlockDoes Onxeo SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Onxeo SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Onxeo SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Onxeo SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Onxeo SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Onxeo SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Onxeo SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Onxeo SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Onxeo SA disclose its waste policy?
Sign up for free to unlockDoes Onxeo SA report according to TCFD requirements?
Sign up for free to unlockDoes Onxeo SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Onxeo SA disclose energy use targets?
Sign up for free to unlockDoes Onxeo SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Onxeo SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Onxeo SA
These potential risks are based on the size, segment and geographies of the company.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France.